CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).…Read More
Intellia Therapeutics Receives Priority Medicines PRIME Designation From the European Medicines Agency for NTLA2002 an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
